中文摘要
胰腺导管腺癌(PDAC)是一种侵袭性肿瘤,生存率低且治疗选择有限。PDAC对免疫治疗策略的耐药性由多因素造成,但部分归因于免疫抑制性肿瘤免疫微环境(TiME)。然而,PDAC的TiME具有异质性,并包含有利的TIL(肿瘤浸润淋巴细胞)群体。三级淋巴结构(TLS)是在慢性炎症条件下于非淋巴组织中形成的免疫细胞有序聚集体,可见于多种情况,包括癌症。我们目前对其在PDAC TiME中作用的理解仍然有限;TLS是复杂结构,具有多种解剖学特征,如位置、密度和成熟度,这些特征可能影响PDAC的临床结局,如生存和治疗反应。同样,我们对操纵TLS方法的理解是一个正在积极发展的研究领域。TLS可能作为抗肿瘤免疫龛发挥作用,可被用作治疗策略,以增强现有化疗方案,并增强未来基于免疫的治疗策略,从而改善患者结局。本综述旨在涵盖TLS在PDAC背景下的解剖学、相关特征、免疫效应、转化意义以及未来研究方向。
展开英文摘要原文
Pancreatic adenocarcinoma (PDAC) is an aggressive tumor with poor survival and limited treatment options. PDAC resistance to immunotherapeutic strategies is multifactorial, but partially owed to an immunosuppressive tumor immune microenvironment (TiME).
However, the PDAC TiME is heterogeneous and harbors favorable tumor-infiltrating lymphocyte (TIL) populations. Tertiary lymphoid structures (TLS) are organized aggregates of immune cells that develop within non-lymphoid tissue under chronic inflammation in multiple contexts, including cancers.
Our current understanding of their role within the PDAC TiME remains limited; TLS are complex structures with multiple anatomic features such as location, density, and maturity that may impact clinical outcomes such as survival and therapy response in PDAC. Similarly, our understanding of methods to manipulate TLS is an actively developing field of research.
TLS may function as anti-tumoral immune niches that can be leveraged as a therapeutic strategy to potentiate both existing chemotherapeutic regimens and potentiate future immune-based therapeutic strategies to improve patient outcomes. This review seeks to cover anatomy, relevant features, immune effects, translational significance, and future directions of understanding TLS within the context of PDAC.
论文信息
- 作者
- Gao Z、Azar J、Zhu H、Williams-Perez S、Kang SW、Marginean C、Rubinstein MP、Makawita S
- 单位
- Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX, United States.United States
- 文献类型
- 综述 · 美国 NIH 资助研究 · 美国政府(非公共卫生署)资助研究 · 非美国政府资助研究
- 期刊
- Frontiers in immunology2024